Q-omics provides the consensus-scored SLAIN2 profile across patient tissues and cancer cell-line models. SLAIN2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLAIN2 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, SLAIN2 RNA expression shows 21,009 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where SLAIN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLAIN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLAIN2 survival associations across molecular data types. SLAIN2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLAIN2 RNA expression–survival associations across cancer types. High SLAIN2 expression shows unfavorable associations in UVM, LGG, PAAD and CESC, but favorable associations in KIRC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLAIN2 RNA expression.
This table summarizes SLAIN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLAIN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLAIN2 shows lower tumor expression in BLCA, LUAD, COAD and READ and higher tumor expression in LIHC and CHOL. The BLCA box plot shows higher SLAIN2 RNA expression in normal versus tumor tissue (log2 FC = −0.680, t-test p < 0.001).
This table shows molecular features associated with SLAIN2 in patient tissues and cancer cell lines. In patient samples, SLAIN2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLAIN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
